0000839087 false Q3 --12-31 true 0000839087 2026-07-01 2026-09-30 0000839087 2022-12-31 2022-12-31 0000839087 2026-01-01 2026-09-30 0000839087 us-gaap:RelatedPartyMember 2025-12-31 0000839087 us-gaap:RelatedPartyMember 2026-09-30 0000839087 2025-01-01 2025-09-30 0000839087 2025-07-01 2025-09-30 0000839087 2025-12-31 0000839087 2026-09-30 0000839087 vaso:CommissionRevenuesMember 2025-01-01 2025-12-31 0000839087 vaso:CommissionRevenuesMember 2026-01-01 2026-09-30 0000839087 vaso:ExtendedServiceContractsMember 2025-01-01 2025-12-31 0000839087 2024-12-31 0000839087 srt:MinimumMember 2026-09-30 0000839087 srt:MaximumMember 2026-09-30 0000839087 us-gaap:SoftwareInDevelopmentMember 2025-12-31 0000839087 us-gaap:SoftwareInDevelopmentMember 2026-09-30 0000839087 us-gaap:PatentedTechnologyMember 2025-12-31 0000839087 us-gaap:PatentedTechnologyMember 2026-09-30 0000839087 us-gaap:CustomerRelationshipsMember 2025-12-31 0000839087 us-gaap:CustomerRelationshipsMember 2026-09-30 0000839087 2025-01-01 2025-12-31 0000839087 us-gaap:CashAndCashEquivalentsMember 2025-12-31 0000839087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2025-12-31 0000839087 us-gaap:CashAndCashEquivalentsMember 2026-09-30 0000839087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CashAndCashEquivalentsMember 2026-09-30 0000839087 us-gaap:CustomerConcentrationRiskMember vaso:GEHCMember vaso:AccountsAndOtherReceivablesMember 2025-01-01 2025-12-31 0000839087 vaso:GEHCMember vaso:AccountsAndOtherReceivablesMember 2025-12-31 0000839087 us-gaap:CustomerConcentrationRiskMember vaso:GEHCMember vaso:AccountsAndOtherReceivablesMember 2026-01-01 2026-09-30 0000839087 vaso:GEHCMember vaso:AccountsAndOtherReceivablesMember 2026-09-30 0000839087 us-gaap:CustomerConcentrationRiskMember vaso:GEHealthcareMember us-gaap:SalesRevenueNetMember 2025-01-01 2025-09-30 0000839087 us-gaap:CustomerConcentrationRiskMember vaso:GEHealthcareMember us-gaap:SalesRevenueNetMember 2026-01-01 2026-09-30 0000839087 us-gaap:CustomerConcentrationRiskMember vaso:GEHealthcareMember us-gaap:SalesRevenueNetMember 2025-07-01 2025-09-30 0000839087 us-gaap:CustomerConcentrationRiskMember vaso:GEHealthcareMember us-gaap:SalesRevenueNetMember 2026-07-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember 2025-12-31 0000839087 us-gaap:AllOtherSegmentsMember 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember us-gaap:CorporateMember 2025-12-31 0000839087 us-gaap:AllOtherSegmentsMember us-gaap:CorporateMember 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:EquipmentsMember 2025-12-31 0000839087 us-gaap:AllOtherSegmentsMember vaso:EquipmentsMember 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ProfessionalSalesServicesMember 2025-12-31 0000839087 us-gaap:AllOtherSegmentsMember vaso:ProfessionalSalesServicesMember 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember 2025-01-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember 2026-01-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember 2026-07-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember us-gaap:CorporateMember 2025-01-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:EquipmentsMember 2025-01-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:EquipmentsMember 2026-01-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:EquipmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:EquipmentsMember 2026-07-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ProfessionalSalesServicesMember 2025-01-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ProfessionalSalesServicesMember 2026-01-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ProfessionalSalesServicesMember 2025-07-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ProfessionalSalesServicesMember 2026-07-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember us-gaap:CorporateMember 2026-01-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember us-gaap:CorporateMember 2025-07-01 2025-09-30 0000839087 us-gaap:AllOtherSegmentsMember us-gaap:CorporateMember 2026-07-01 2026-09-30 0000839087 vaso:ContractsMember 2024-12-31 0000839087 vaso:ContractsMember 2025-12-31 0000839087 vaso:ContractsMember 2026-09-30 0000839087 vaso:VasoHealthcareBusinessMember 2025-12-31 0000839087 vaso:VasoHealthcareBusinessMember 2026-09-30 0000839087 vaso:RevenueRecognitionThereafterMember 2026-09-30 0000839087 vaso:RevenueRecognition2028Member 2026-09-30 0000839087 vaso:RevenueRecognition2027Member 2026-09-30 0000839087 vaso:RevenueRecognitionYearTwoMember 2026-09-30 0000839087 vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredOverTimeMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredOverTimeMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:CommissionsMember 2025-01-01 2025-09-30 0000839087 vaso:CommissionsMember vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:CommissionsMember 2026-01-01 2026-09-30 0000839087 vaso:CommissionsMember vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember 2025-01-01 2025-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:CommissionsMember 2025-07-01 2025-09-30 0000839087 vaso:CommissionsMember vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:CommissionsMember 2026-07-01 2026-09-30 0000839087 vaso:CommissionsMember vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember 2025-07-01 2025-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 us-gaap:DiscontinuedOperationsHeldforsaleMember 2025-12-31 0000839087 vaso:NetWolvesMember 2025-01-01 2025-09-30 0000839087 vaso:NetWolvesMember 2026-01-01 2026-09-30 0000839087 vaso:NetWolvesMember 2025-07-01 2025-09-30 0000839087 vaso:NetWolvesMember 2026-07-01 2026-09-30 0000839087 us-gaap:SegmentDiscontinuedOperationsMember 2026-01-01 2026-09-30 0000839087 us-gaap:SegmentDiscontinuedOperationsMember 2026-09-30 0000839087 vaso:EECPGlobalCorporationMember 2026-09-30 0000839087 2025-09-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-09-30 0000839087 us-gaap:RetainedEarningsMember 2026-09-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2026-09-30 0000839087 us-gaap:CommonStockMember 2026-09-30 0000839087 us-gaap:RetainedEarningsMember 2026-07-01 2026-09-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-07-01 2026-09-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2026-07-01 2026-09-30 0000839087 us-gaap:CommonStockMember 2026-07-01 2026-09-30 0000839087 2026-06-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-06-30 0000839087 us-gaap:RetainedEarningsMember 2026-06-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000839087 us-gaap:CommonStockMember 2026-06-30 0000839087 2026-04-01 2026-06-30 0000839087 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-04-01 2026-06-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000839087 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000839087 2026-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-03-31 0000839087 us-gaap:RetainedEarningsMember 2026-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000839087 us-gaap:CommonStockMember 2026-03-31 0000839087 2026-01-01 2026-03-31 0000839087 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2026-01-01 2026-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-12-31 0000839087 us-gaap:RetainedEarningsMember 2025-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000839087 us-gaap:CommonStockMember 2025-12-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-09-30 0000839087 us-gaap:RetainedEarningsMember 2025-09-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0000839087 us-gaap:CommonStockMember 2025-09-30 0000839087 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-07-01 2025-09-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0000839087 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0000839087 2025-06-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0000839087 us-gaap:RetainedEarningsMember 2025-06-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000839087 us-gaap:CommonStockMember 2025-06-30 0000839087 2025-04-01 2025-06-30 0000839087 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000839087 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000839087 2025-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0000839087 us-gaap:RetainedEarningsMember 2025-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000839087 us-gaap:CommonStockMember 2025-03-31 0000839087 2025-01-01 2025-03-31 0000839087 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000839087 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0000839087 us-gaap:RetainedEarningsMember 2024-12-31 0000839087 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000839087 us-gaap:CommonStockMember 2024-12-31 0000839087 vaso:CostOfEquipmentSalesAndServicesMember 2025-01-01 2025-09-30 0000839087 vaso:CostOfEquipmentSalesAndServicesMember 2026-01-01 2026-09-30 0000839087 vaso:CostOfEquipmentSalesAndServicesMember 2025-07-01 2025-09-30 0000839087 vaso:CostOfEquipmentSalesAndServicesMember 2026-07-01 2026-09-30 0000839087 vaso:CostOfProfessionalSalesServicesMember 2025-01-01 2025-09-30 0000839087 vaso:CostOfProfessionalSalesServicesMember 2026-01-01 2026-09-30 0000839087 vaso:CostOfProfessionalSalesServicesMember 2025-07-01 2025-09-30 0000839087 vaso:CostOfProfessionalSalesServicesMember 2026-07-01 2026-09-30 0000839087 vaso:CostOfManagedITSystemsAndServicesMember 2025-01-01 2025-09-30 0000839087 vaso:CostOfManagedITSystemsAndServicesMember 2025-07-01 2025-09-30 0000839087 vaso:EquipmentSalesAndServicesMember 2025-01-01 2025-09-30 0000839087 vaso:EquipmentSalesAndServicesMember 2026-01-01 2026-09-30 0000839087 vaso:EquipmentSalesAndServicesMember 2025-07-01 2025-09-30 0000839087 vaso:EquipmentSalesAndServicesMember 2026-07-01 2026-09-30 0000839087 vaso:ProfessionalSalesServicesMember 2025-01-01 2025-09-30 0000839087 vaso:ProfessionalSalesServicesMember 2026-01-01 2026-09-30 0000839087 vaso:ProfessionalSalesServicesMember 2025-07-01 2025-09-30 0000839087 vaso:ProfessionalSalesServicesMember 2026-07-01 2026-09-30 0000839087 vaso:ManagedITSystemsAndServicesMember 2025-01-01 2025-09-30 0000839087 vaso:ManagedITSystemsAndServicesMember 2025-07-01 2025-09-30 0000839087 2026-11-12 0000839087 vaso:CommissionsMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 vaso:CommissionsMember vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:CommissionsMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 vaso:CommissionsMember vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ITSegmentMember 2025-07-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember 2026-01-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:CommissionsMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 vaso:CommissionsMember vaso:EquipmentSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:CommissionsMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 vaso:CommissionsMember vaso:EquipmentSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentSalesMember vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ITSegmentMember 2025-01-01 2025-09-30 0000839087 vaso:MedicalEquipmentServiceMember vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2026-01-01 2026-09-30 0000839087 us-gaap:TransferredOverTimeMember vaso:ProfessionalSalesServiceSegmentsMember 2025-01-01 2025-09-30 0000839087 us-gaap:TransferredAtPointInTimeMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2026-09-30 0000839087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CashAndCashEquivalentsMember 2026-09-30 0000839087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel2Member us-gaap:CashAndCashEquivalentsMember 2025-12-31 0000839087 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member us-gaap:CashAndCashEquivalentsMember 2025-12-31 0000839087 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000839087 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000839087 vaso:ManagedITSystemsAndServicesMember 2026-07-01 2026-09-30 0000839087 vaso:ManagedITSystemsAndServicesMember 2026-01-01 2026-09-30 0000839087 vaso:CostOfManagedITSystemsAndServicesMember 2026-07-01 2026-09-30 0000839087 vaso:CostOfManagedITSystemsAndServicesMember 2026-01-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 us-gaap:AllOtherSegmentsMember vaso:ITSegmentMember 2026-01-01 2026-09-30 0000839087 vaso:ExtendedServiceContractsMember 2026-01-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ITSegmentMember 2026-07-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ProfessionalSalesServiceSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:EquipmentSegmentsMember 2026-07-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember 2026-07-01 2026-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:ProfessionalSalesServiceSegmentsMember 2025-07-01 2025-09-30 0000839087 vaso:SoftwareSalesAndSupportMember vaso:EquipmentSegmentsMember 2025-07-01 2025-09-30 0000839087 us-gaap:DiscontinuedOperationsHeldforsaleMember 2026-09-30 iso4217:USD xbrli:shares xbrli:pure vaso:segments iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the quarterly period ended September 30, 2026

 

☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

For the transition period from _______________ to ______________

 

Commission File Number: 0-18105

 

 

VASO CORPORATION

 

(Exact name of registrant as specified in its charter)

 

Delaware   11-2871434

(State or other jurisdiction of

incorporation or organization)

 

(IRS Employer

Identification Number)

 

137 Commercial St., Suite 200, Plainview, New York 11803

 

(Address of principal executive offices)

 

Registrant’s Telephone Number (516) 997-4600

 

Securities registered pursuant to Section 12 (b) of the Act: None

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large Accelerated Filer ☐ Accelerated Filer ☐ Non-Accelerated Filer ☒ Smaller Reporting Company ☒
Emerging Growth Company ☐      

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

 

Number of Shares Outstanding of Common Stock, $.001 Par Value, at November 12, 2026 – 176,238,225

 

 

 

 

 

 

Vaso Corporation and Subsidiaries

 

INDEX

 

PART I – FINANCIAL INFORMATION   1
     
ITEM 1 - FINANCIAL STATEMENTS   1
     
CONDENSED CONSOLIDATED BALANCE SHEETS as of September 30, 2026 (unaudited) and December 31, 2025   1
     
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (unaudited) for the Three and Nine Months Ended September 30, 2026 and 2025   2
     
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (unaudited) for the Three and Nine Months Ended September 30, 2026 and 2025   3
     
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited) for the Nine Months Ended September 30, 2026 and 2025   4
     
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)   5
     
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS   19
     
ITEM 3 - Quantitative and Qualitative Disclosures About Market Risk.   26
     
ITEM 4 - CONTROLS AND PROCEDURES   26
     
PART II - OTHER INFORMATION   27
     
ITEM 1 – LEGAL PROCEEDINGS   27
     
ITEM 1A. Risk Factors.   27
     
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.   27
     
ITEM 3. Defaults Upon Senior Securities.   27
     
ITEM 4. Mine Safety Disclosures.   27
     
ITEM 5. Other Information.   27
     
ITEM 6 – EXHIBITS   27

 

Page i

 

 

PART I – FINANCIAL INFORMATION

 

ITEM 1 - FINANCIAL STATEMENTS

 

Vaso Corporation and Subsidiaries

 

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

    September 30, 2026     December 31, 2025  
    (unaudited)        
ASSETS            
CURRENT ASSETS            
Cash and cash equivalents   $ 49,947     $ 34,081  
Restricted cash     2,850       -  
Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $12,106 at September 30, 2026 and $11,215 at December 31, 2025     5,602       13,293  
Receivables due from related parties     1,415       926  
Inventories, net     812       833  
Deferred commission expense     4,310       3,789  
Prepaid expenses and other current assets     636       1,055  
Current assets held for sale     -       4,583  
Total current assets     65,572       58,560  
                 
Property and equipment, net of accumulated depreciation of$1,295 at September 30, 2026 and $1,233 at December 31, 2025     89       121  
Operating lease right of use assets     1,529       1,152  
Goodwill     1,279       1,225  
Intangibles, net     1,890       1,255  
Other assets, net     5,385       5,989  
Investment in EECP Global     -       135  
Deferred tax assets, net     7,253       8,924  
Noncurrent assets held for sale     -       11,958  
Total assets   $ 82,997     $ 89,319  
                 
LIABILITIES AND STOCKHOLDERS' EQUITY                
CURRENT LIABILITIES                
Accounts payable   $ 619     $ 896  
Accrued commissions     1,325       2,575  
Accrued expenses and other liabilities     5,095       8,352  
Accumulated losses on unconsolidated investees in excess of investment     51       -  
Operating lease liabilities - current     764       689  
Sales tax payable     211       244  
Deferred revenue - current portion     21,118       19,018  
Notes payable - current portion     -       286  
Due to related party     3       3  
Current liabilities held for sale     -       4,783  
Total current liabilities     29,186       36,846  
                 
LONG-TERM LIABILITIES                
Operating lease liabilities, net of current portion     765       464  
Deferred revenue, net of current portion     20,422       19,577  
Other long-term liabilities     1,715       1,906  
Noncurrent liabilities held for sale     -       1,097  
Total long-term liabilities     22,902       23,044  
                 
COMMITMENTS AND CONTINGENCIES (NOTE O)                
                 
STOCKHOLDERS' EQUITY                
Preferred stock, $.01 par value; 1,000,000 shares authorized; nil shares issued and outstanding at September 30, 2026 and December 31, 2025     -       -  
Common stock, $.001 par value; 250,000,000 shares authorized; 176,238,225 and 175,953,035 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively     176       176  
Additional paid-in capital     62,105       62,080  
Accumulated deficit     (31,183 )     (32,512 )
Accumulated other comprehensive loss     (189 )     (315 )
Total stockholders’ equity     30,909       29,429  
Total liabilities and stockholders' equity   $ 82,997     $ 89,319  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

Page 1

 

 

Vaso Corporation and Subsidiaries

 

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME

(unaudited)

(in thousands, except per share data)

 

    Three Months ended
September 30,
    Nine Months ended
September 30,
 
    2026     2025     2026     2025  
Revenues                        
Managed IT systems and services   $ -     $ 938     $ -     $ 2,983  
Professional sales services     10,148       10,820       29,877       28,269  
Equipment sales and services     638       619       1,890       1,589  
Total revenues     10,786       12,377       31,767       32,841  
                                 
Cost of revenues                                
Cost of managed IT systems and services     -       551       -       1,711  
Cost of professional sales services     1,955       2,073       5,992       5,542  
Cost of equipment sales and services     267       203       801       460  
Total cost of revenues     2,222       2,827       6,793       7,713  
Gross profit     8,564       9,550       24,974       25,128  
                                 
Operating expenses                                
Selling, general and administrative     7,696       8,024       23,791       23,775  
Research and development     236       146       631       491  
Total operating expenses     7,932       8,170       24,422       24,266  
Operating income     632       1,380       552       862  
                                 
Other (expense) income                                
Interest and other income, net     299       198       756       629  
Total other income, net     299       198       756       629  
                                 
Income before income taxes     931       1,578       1,308       1,491  
Income tax expense     (363 )     (25 )     (625 )     (80 )
Net income from continuing operations     568       1,553       683       1,411  
Net income (loss) from discontinued operations, net of tax     1,104       158       646       (972 )
Net income     1,672       1,711       1,329       439  
                                 
Other comprehensive income                                
Foreign currency translation gain     23       16       126       72  
Comprehensive income   $ 1,695     $ 1,727     $ 1,455     $ 511  
                                 
Income (loss) per common share                                
- basic and diluted - continuing operations   $ 0.00     $ 0.01     $ 0.00     $ 0.01  
- basic and diluted - discontinued operations     0.01       0.00       0.00       (0.01 )
- basic and diluted   $ 0.01     $ 0.01     $ 0.01     $ 0.00  
                                 
Weighted average common shares outstanding                                
- basic     176,159       175,862       176,043       175,767  
- diluted     176,374       175,922       176,225       175,941  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

Page 2

 

 

Vaso Corporation and Subsidiaries

 

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(in thousands)

 

    Common Stock     Additional Paid-in-     Accumulated     Accumulated Other Comprehensive     Total Stockholders’  
    Shares     Amount     Capital     Deficit     Loss     Equity  
                                     
Balance at January 1, 2025     175,696     $        176     $ 62,049     $    (34,081 )   $          (442 )   $ 27,702  
Share-based compensation     -       -       8       -       -       8  
Foreign currency translation gain     -       -       -       -       15       15  
Net loss     -       -       -       (1,075 )     -       (1,075 )
Balance at March 31, 2025     175,696     $ 176     $ 62,057     $ (35,156 )   $ (427 )   $ 26,650  
Share-based compensation     57       -       8       -       -       8  
Shares withheld for employee tax liability     -       -       (1 )     -       -       (1 )
Foreign currency translation gain     -       -       -       -       41       41  
Net loss     -       -       -       (197 )     -       (197 )
Balance at June 30, 2025     175,753     $ 176     $ 62,064     $ (35,353 )   $ (386 )   $ 26,501  
Share-based compensation     200       -       8       -       -       8  
Foreign currency translation gain     -       -       -       -       16       16  
Net income     -       -       -       1,711       -       1,711  
Balance at September 30, 2025     175,953     $ 176     $ 62,072     $ (33,642 )   $ (370 )   $ 28,236  
                                                 
Balance at January 1, 2026     175,953     $ 176     $ 62,080     $ (32,512 )   $ (315 )   $ 29,429  
Share-based compensation     -       -       8       -       -       8  
Foreign currency translation gain     -       -       -       -       52       52  
Net loss     -       -       -       (887 )     -       (887 )
Balance at March 31, 2026     175,953     $ 176     $ 62,088     $ (33,399 )   $ (263 )   $ 28,602  
Share-based compensation     65       -       11       -       -       11  
Foreign currency translation gain     -       -       -       -       51       51  
Net income     -       -       -       544       -       544  
Balance at June 30, 2026     176,018     $ 176     $ 62,099     $ (32,855 )   $ (212 )   $ 29,208  
Share-based compensation     220       -       28       -       -       28  
Shares withheld for employee tax liablility                     (22 )                     (22 )
Shares withheld for employee tax liability     -       -       (22 )     -       -       (22 )
Foreign currency translation gain     -       -       -       -       23       23  
Net income     -       -       -       1,672       -       1,672  
Balance at September 30, 2026     176,238     $ 176     $ 62,105     $ (31,183 )   $ (189 )   $ 30,909  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

Page 3

 

 

Vaso Corporation and Subsidiaries

 

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (unaudited)

(in thousands)

 

    Nine Months Ended  
    September 30,  
    2026     2025  
Cash flows from operating activities            
Net income   $ 1,329     $ 439  
Adjustments to reconcile net income to net                
cash provided by operating activities                
Depreciation and amortization     636       531  
Deferred income taxes     1,480       -  
Loss from investment in EECP Global     186       220  
Gain on divestiture of NetWolves     (3,494 )     -  
Provision for credit losses and commission adjustments     259       264  
Share-based compensation     47       25  
Changes in operating assets and liabilities:                
Accounts and other receivables     7,717       7,573  
Due from related parties     (501 )     (186 )
Inventories     111       41  
Deferred commission expense     (521 )     245  
Prepaid expenses and other current assets     419       3  
Other assets, net     694       (1,428 )
Accounts payable     70       (233 )
Accrued commissions     (1,228 )     (1,373 )
Accrued expenses and other liabilities     (3,364 )     (2,154 )
Sales tax payable     (54 )     (68 )
Deferred revenue     2,946       4,518  
Other long-term liabilities     (191 )     595  
Net cash provided by operating activities     6,541       9,012  
                 
Cash flows from investing activities                
Purchases of equipment and software     (1,261 )     (642 )
Net proceeds from divestiture of NetWolves     12,806       -  
Net cash provided by (used in) investing activities     11,545       (642 )
                 
Cash flows from financing activities                
Payroll taxes paid by withholding shares     (22 )     (1 )
Proceeds from note payable     -       1,243  
Repayment of notes payable     (293 )     (996 )
Net cash (used in) provided by financing activities     (315 )     246  
                 
Effect of exchange rate differences on cash and cash equivalents     (24 )     (28 )
                 
NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH     17,747       8,588  
Cash, cash equivalents and restricted cash - beginning of period, including cash from discontinued operations     35,050       26,271  
Cash, cash equivalents and restricted cash - end of period, including cash from discontinued operations   $ 52,797     $ 34,859  
                 
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION                
Interest paid   $ -     $ 1  
Income taxes paid   $ 165     $ 189  
                 
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES                
Initial recognition of operating lease right of use asset and liability   $ 992     $ 167  
Transfer of fixed assets to inventory   $ 53     $ 166  

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

Page 4

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

NOTE A - ORGANIZATION AND PLAN OF OPERATIONS

 

Vaso Corporation was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.

 

Overview

 

Prior to the two divestitures described below, Vaso Corporation (the “Company”) principally operates in three distinct business segments in the healthcare equipment and information technology industries. We managed and evaluated our operations, and reported our financial results, through these three business segments:

 

● IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focuses on managed network technology services. As described in Note C, the NetWolves managed network services operations are reported as discontinued operations, thus no longer included in segment disclosures, and were divested on July 31, 2026. Historical results of VasoHeathcare IT Corp, the other operation within the IT segment, and which was sold in November 2025, continue to be presented in the comparative prior-year IT segment disclosures;

 

● Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE Healthcare Technologies, Inc. (“GEHC”) into the healthcare provider middle market; and

 

● Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. (“VasoSolutions”) for domestic business and Vasomedical Global Corp. (“Vasomedical Global”) for international business, respectively, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software. VasoSolutions also manages the domestic operation of EECP Global Corporation (“EECP Global”), in which the Company holds a 49% minority interest.

 

The Company’s website is www.vasocorporation.com.

 

VasoTechnology (IT Segment)

 

VasoTechnology, Inc. was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). VasoTechnology consisted of a managed network and security service division (NetWolves), until July 2026, upon which time NetWolves was sold to COEO Solutions, LLC, and a healthcare IT application VAR (value added reseller) division, VasoHealthcare IT (“VHC-IT”), until November 2025, upon which time the Company sold VHC-IT to Nano-X Imaging Ltd (Nasdaq: NNOX). As such, the Company has completed its exit from the network and IT services businesses under VasoTechnology (IT segment).

 

VasoHealthcare (Professional Sales Service Segment)

 

VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement with GEHC (“GEHC Agreement”) to further the sale of certain healthcare capital equipment in the healthcare provider middle market. Its current offerings consist of:

 

● GEHC diagnostic imaging capital equipment and ultrasound systems;

 

● GEHC service agreements for the above equipment;

 

● GEHC training services for use of the above equipment; and

 

● GEHC and third-party financial services for the above equipment.

 

Page 5

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

VasoMedical (Equipment Segment)

 

VasoMedical is the Company’s business division for its proprietary medical device operations, including the design, development, manufacturing, sales and service of various medical devices in the domestic and international markets and includes the Vasomedical Global and Vasomedical Solutions business units. These devices are primarily for cardiovascular monitoring and diagnostic systems. Its current offerings consist of:

 

● Biox™ series Holter monitors and ambulatory blood pressure recorders;

 

● ARCS® series analysis, reporting and communication software for ECG and blood pressure signals, including cloud-based software suite and algorithm in the form of a SaaS (software as a service) subscription;

 

● MobiCare® multi-parameter wireless vital-sign monitoring system; and

 

● EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease.

 

This segment uses its extensive in-house knowledge and intellectual property for cardiovascular devices and software coupled with its engineering resources to cost-effectively create and market its proprietary technology. It sells and services its products to customers in the U.S. and China directly and sells and/or services its products in the international market mainly through independent distributors.

 

Divestiture of NetWolves

 

On July 31, 2026, the Company, VasoTechnology, NetWolves, and COEO Solutions, LLC, an Illinois limited liability company (“Buyer”), entered into an Equity Purchase Agreement (the “Purchase Agreement”), pursuant to which Buyer purchased from the Company and VasoTechnology all of the issued and outstanding membership interests of NetWolves.

 

The base purchase price under the Purchase Agreement was $14,500,000 in cash, subject to customary post-closing adjustments based on net working capital, closing cash, closing indebtedness and unpaid seller expenses, as more fully described in the Purchase Agreement.

 

Restricted cash of $2,850,000 at September 30, 2026 represents the portion of the purchase price deposited in escrow to secure the Company’s purchase price adjustments and indemnification obligations under the Purchase Agreement, which are expected to be released by October 31, 2027.

 

See Note C - DISCONTINUED OPERATIONS of the notes to condensed consolidated financial statements.

 

NOTE B – INTERIM STATEMENT PRESENTATION

 

Basis of Presentation and Use of Estimates

 

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial information. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on March 31, 2026.

 

Page 6

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.

 

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The most significant of these estimates include the allowance for commission adjustments, the valuation of deferred tax assets, and the assessment of possible impairment of goodwill and intangible assets. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company’s management. The Company evaluates its estimates and assumptions on an ongoing basis.

 

Recalssifications

 

Certain reclassifications have been made to prior year amounts to conform with the current year presentation.

 

Recently Issued Accounting Standards To Be Adopted

 

In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses, which requires disclosure of disaggregated information about certain income statement line items in the notes to the financial statements. The ASU is effective for fiscal years beginning after December 15, 2026, and interim periods within annual reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.

 

In September 2025, the FASB issued ASU 2025-06, Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Accounting for and Disclosure of Software Costs, which amends certain aspects of the accounting for and disclosure of internal-use software costs. The ASU is effective for annual reporting periods beginning with the year ending December 31, 2028. Early adoption is permitted. The Company is currently evaluating the impact of adopting this standard on its Consolidated Financial Statements.

 

NOTE C – DISCONTINUED OPERATIONS

 

On July 31, 2026, the Company completed the sale of its NetWolves business to COEO Solutions, LLC. The results of the NetWolves operations are presented as net income (loss) from discontinued operations, net of income taxes on the Company’s condensed consolidated statements of operations and, as such, have been excluded from both continuing operations and segment results for all periods presented. The condensed consolidated statements of cash flows are presented on a consolidated basis for both continuing operations and discontinued operations. Unless otherwise noted, reference within the notes to condensed consolidated financial statements relates to continuing operations.

 

Page 7

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

The following table presents the allocation of sales price and calculation of gain on disposal of NetWolves:

 

    (in thousands)  
Sale price   $ 14,500  
         
Closing cash     555  
Closing indebtedness     (1,084 )
Unpaid seller expenses     (971 )
Working capital adjustment     (459 )
Net proceeds   $ 12,541  
         
Allocation of Acquisition value:        
Assets disposed:        
Accounts receivable     (2,532 )
Prepaid expenses and other current assets     (980 )
Property and equipment     (1,188 )
Operating lease right of use assets     (275 )
Goodwill     (9,736 )
Intangibles, net     (599 )
Other assets, net     (27 )
Total assets disposed   $ (15,336 )
Liabilities disposed        
Accounts payable     (3,461 )
Accrued commissions     (2 )
Accrued expenses and other liabilities     (1,254 )
Sales tax payable     (518 )
Operating lease liabilities - current     (245 )
Deferred tax liabilities     (779 )
Operating lease liabilities, net of current portion     (29 )
Total liabilities disposed   $ (6,289 )
Total estimated fair value of net assets   $ (9,047 )
         
Gain on sale of NetWolves   $ 3,494  

 

The following table presents the major components of financial results of the NetWolves operation for the periods presented:

 

    (in thousands)  
    Three Months ended
September 30,
    Nine Months ended
September 30,
 
    2026     2025     2026     2025  
                         
Revenue   $ 3,230     $ 10,280     $ 22,463     $ 29,234  
Cost of revenue     1,973       5,934       12,910       17,309  
Gross profit     1,257       4,346       9,553       11,925  
Selling, general and administrative     2,415       4,188       11,386       12,888  
Operating income (loss)     (1,158 )     158       (1,833 )     (963 )
Other (expense) income                                
Interest and other income, net     6       11       99       32  
Gain on sale of subsidiary     3,494       -       3,494       -  
Loss on disposal of fixed assets     (1 )     (1 )     (6 )     (6 )
Total other income, net     3,499       10       3,587       26  
                                 
Net income (loss) from discontinued operations before income taxes     2,341       168       1,754       (937 )
Income tax expense     (1,237 )     (10 )     (1,108 )     (35 )
Net income (loss) from discontinued operations, net of income taxes     1,104       158       646       (972 )

  

Page 8

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

The following table represents the aggregated carrying amounts of classes of assets and liabilities that are classified as held for sale on the condensed consolidated balance sheets for the periods presented:

 

    September 30,
2026
    December 31,
2025
 
    (unaudited)     (unaudited)  
ASSETS            
CURRENT ASSETS            
Cash and cash equivalents   $             -     $ 969  
Accounts and other receivables, net of an allowance for credit losses and commission adjustments of $0 at September 30, 2026 and $197 at December 31, 2025     -       2,642  
Prepaid expenses and other current assets     -       972  
Total current assets held for sale     -       4,583  
                 
Property and equipment, net of accumulated depreciation of $0 at September 30, 2026 and $7,898 at December 31, 2025     -       1,142  
Operating lease right of use assets     -       373  
Goodwill     -       9,736  
Intangibles, net     -       680  
Other assets, net     -       27  
Total noncurrent assets held for sale   $ -     $ 11,958  
                 
LIABILITIES                
CURRENT LIABILITIES                
Accounts payable     -       3,112  
Accrued commissions     -       32  
Accrued expenses and other liabilities     -       859  
Operating lease liabilities - current     -       245  
Sales tax payable     -       535  
Total current liabilities held for sale     -       4,783  
                 
LONG-TERM LIABILITIES                
Operating lease liabilities, net of current portion     -       127  
Deferred tax liability     -       970  
Total noncurrent liabilities held for sale     -       1,097  

 

Cash flows from discontinued operations not separately presented on the face of the condensed consolidated statement of cash flows. The following table presents significant non-cash items and capital expenditures of discontinued operations for the periods presented:

 

    (in thousands)  
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
                         
Depreciation and amortization   $ 41     $ 124     $ 278     $ 349  
Deferred income taxes     1,123       -       966     $ -  
Gain on divestiture of NetWolves     (3,494 )     -       (3,494 )     -  
Credit loss expense     82       36       224       108  
Capital expenditures     12       (314 )     297       152  

 

Page 9

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

NOTE D – REVENUE RECOGNITION

 

Disaggregation of Revenue

 

The following tables present revenues disaggregated by our business operations and timing of revenue recognition:

 

    (in thousands)  
    Three Months Ended
September 30, 2026
    Three Months Ended
September 30, 2025
 
    IT     Professional sales
service
    Equipment           IT     Professional sales
service
    Equipment        
    segment     segment     segment     Total     segment     segment     segment     Total  
Software sales and support     -       -       -       -       938       -       -       938  
Commissions     -       10,148       -       10,148       -       10,820       -       10,820  
Medical equipment sales     -       -       608       608       -       -       588       588  
Medical equipment service     -       -       30       30       -       -       31       31  
    $ -     $ 10,148     $ 638     $ 10,786     $ 938     $ 10,820     $ 619     $ 12,377  

 

    Nine Months Ended
September 30, 2026
    Nine Months Ended
September 30, 2025
 
          Professional sales     Equipment                 Professional sales     Equipment        
    IT segment     service segment     segment     Total     IT segment     service segment     segment     Total  
Software sales and support        -       -       -       -       2,983       -       -       2,983  
Commissions     -       29,877       -       29,877       -       28,269       -       28,269  
Medical equipment sales     -       -       1,800       1,800       -       -       1,498       1,498  
Medical equipment service     -       -       90       90       -       -       91       91  
    $ -     $ 29,877     $ 1,890     $ 31,767     $ 2,983     $ 28,269     $ 1,589     $ 32,841  

 

    Three Months Ended
September 30, 2026
   

 Three Months Ended
September 30, 2025

 
          Professional sales     Equipment                 Professional sales     Equipment        
    IT segment     service segment     segment     Total     IT segment     service segment     segment     Total  
Revenue recognized over time   $ -     $ -     $ 189     $ 189     $ 803     $ -     $ 80     $ 883  
Revenue recognized at a point in time     -       10,148       449       10,597       135       10,820       539       11,494  
    $ -     $ 10,148     $ 638     $ 10,786     $ 938     $ 10,820     $ 619     $ 12,377  

 

    Nine Months Ended September 30, 2026     Nine Months Ended September 30, 2025  
          Professional sales     Equipment                 Professional sales     Equipment        
    IT segment     service segment     segment     Total     IT segment     service segment     segment     Total  
Revenue recognized over time   $ -     $ -     $ 519     $ 519     $ 2,658     $ -     $ 380     $ 3,038  
Revenue recognized at a point in time     -       29,877       1,371       31,248       325       28,269       1,209       29,803  
    $ -     $ 29,877     $ 1,890     $ 31,767     $ 2,983     $ 28,269     $ 1,589     $ 32,841  

 

Page 10

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

Transaction Price Allocated to Remaining Performance Obligations

 

As of September 30, 2026, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $75.9 million, of which we expect to recognize revenue as follows:

 

    (in thousands)  
    Fiscal years of revenue recognition  
    2026     2027     2028     Thereafter  
Unfulfilled performance obligations   $ 10,892     $ 28,345     $ 9,238     $ 27,417  

 

Contract Assets and Liabilities

 

Contract assets include trade receivables, net and long-term receivables (recorded in Other assets in the condensed consolidated balance sheets). Contract liabilities arise in our VasoHealthcare business, where we bill amounts for certain milestones in advance of customer acceptance of the underlying equipment. Such amounts aggregated approximately $41.5 million and $38.6 million at September 30, 2026 and December 31, 2025, respectively, and are classified in our condensed consolidated balance sheets as either Deferred revenue - current portion or Deferred revenue, net of current portion. In addition, we record a contract liability for amounts expected to be repaid to GEHC due to customer order reductions. Such amounts aggregated approximately $0.5 million and $1.3 million at September 30, 2026 and December 31, 2025, respectively, and are included in Accrued expenses and other liabilities in our condensed consolidated balance sheets.

 

During the three and nine months ended September 30, 2026, we recognized approximately $3.4 million and $8.0 million of revenues, respectively, that were included in our contract liability balance at July 1, 2026 and January 1, 2026, respectively. During the three and nine months ended September 30, 2025, we recognized approximately $3.8 million and $7.0 million of revenues, respectively, that were included in our contract liability balance at July 1, 2025 and January 1, 2025, respectively.

 

The following table summarizes the Company’s contract assets and contract liability balances:

 

    September 30,
2026
    December 31,
2025
    December 31,
2024
 
Contract assets     6,516       14,823       15,566  
Contract liabilities     42,058       39,882       36,007  

 

The decrease in contract assets in the first nine months of 2026 was due primarily to collections exceeding billings. The increase in contract liabilities in the same period is mainly attributable to orders exceeding deliveries.

 

NOTE E – SEGMENT REPORTING AND CONCENTRATIONS

 

Prior to the two divestitures described below, Vaso Corporation principally operated in three distinct business segments in the healthcare and information technology industries. We managed and evaluated our operations, and reported our financial results, through these three reportable segments.

 

● IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focused on healthcare IT and managed network technology services. As described in Note C, the NetWolves managed network services operations are reported as discontinued operations and no longer included in segment disclosures. Historical results of VasoHeathcare IT Corp, the other operation within the IT segment and which was sold in November 2025, continue to be presented in segment disclosures;

 

● Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and

 

● Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices.

 

Page 11

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income and adjusted EBITDA (which is a non-GAAP financial measure defined as net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash stock-based compensation). The chief operating decision maker uses segment operating income, which is the measure most consistent with U.S. GAAP, and adjusted EBITDA primarily to compare segment results against budget and prior periods and to allocate resources, including personnel and capital, among the segments. Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:

 

    (in thousands)  
    Three Months Ended
September 30,
    Nine Months Ended
September 30,
 
    2026     2025     2026     2025  
Revenues from external customers                                
IT   $ -     $ 938     $ -     $ 2,983  
Professional sales service     10,148       10,820       29,877       28,269  
Equipment     638       619       1,890       1,589  
Total revenues   $ 10,786     $ 12,377     $ 31,767     $ 32,841  
                                 
Gross Profit                                
IT   $ -     $ 387     $ -     $ 1,272  
Professional sales service     8,193       8,747       23,885       22,727  
Equipment     371       416       1,089       1,129  
Total gross profit   $ 8,564     $ 9,550     $ 24,974     $ 25,128  
                                 
Significant segment expenses                                
Selling, general & administrative                                
IT   $ -     $ 555     $ -     $ 1,492  
Professional sales service     6,862       6,731       21,208       19,910  
Equipment     435       449       1,353       1,259  
Corporate     399       289       1,230       1,114  
Total selling, general and administrative   $ 7,696     $ 8,024     $ 23,791     $ 23,775  
                                 
Other segment items                                
Equipment     236       146       631       491  
Total other segment items   $ 236     $ 146     $ 631     $ 491  
                                 
Operating income (loss)                                
IT   $ -     $ (168 )   $ -     $ (220 )
Professional sales service     1,331       2,016       2,677       2,817  
Equipment     (300 )     (179 )     (895 )     (621 )
Corporate     (399 )     (289 )     (1,230 )     (1,114 )
Total operating income   $ 632     $ 1,380     $ 552     $ 862  
                                 
Depreciation and amortization                                
IT   $ -     $ 2     $ -     $ 38  
Professional sales service     36       34       99       107  
Equipment     87       18       258       35  
Corporate     -       -       -       -  
Total depreciation and amortization   $ 123     $ 54     $ 357     $ 180  
                                 
Capital expenditures                                
IT   $ -     $ (30 )   $ -     $ 3  
Professional sales service     34       6       286       79  
Equipment     252       113       678       405  
Corporate     -       -       -       3  
Total capital expenditures   $ 286     $ 89     $ 965     $ 490  

 

Page 12

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

    September 30,
2026
    December 31,
2025
 
Identifiable Assets            
Professional sales service     15,578       23,130  
Equipment     6,677       6,643  
Corporate     60,742       43,005  
Total assets, continuing operations   $ 82,997     $ 72,778  

 

GEHC accounted for 94% of revenue for the three months ended September 30, 2026 and 2025, and 87% and 86% of revenue for the nine months ended September 30, 2026 and 2025, respectively. GEHC also accounted for $4.1 million, or 74%, and $12.1 million or 91%, of accounts and other receivables at September 30, 2026 and December 31, 2025, respectively. No other customer accounted for 10% or more of revenue.

 

NOTE F – NET INCOME (LOSS) PER COMMON SHARE

 

Basic earnings (loss) per common share is based on the weighted average number of common shares outstanding, including vested restricted shares, without consideration of potential common stock. Diluted earnings per common share is based on the weighted average number of common and potential dilutive common shares outstanding.

 

Diluted earnings (loss) per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:

 

    (in thousands)  
    Three months ended
September 30,
    Nine months ended
September 30,
 
    2026     2025     2026     2025  
Basic weighted average shares outstanding     176,159       175,862       176,043       175,767  
Dilutive effect of unvested restricted shares     215       60       182       174  
Diluted weighted average shares outstanding     176,374       175,922       176,225       175,941  

 

NOTE G – SHORT-TERM INVESTMENTS AND FINANCIAL INSTRUMENTS

 

Cash and cash equivalents represent cash and short-term, highly liquid investments either in certificates of deposit, treasury bills, money market funds, or investment grade commercial paper issued by major corporations and financial institutions that generally have maturities of three months or less from the date of acquisition.

 

The Company complies with the provisions of ASC 820 “Fair Value Measurements and Disclosures” (“ASC 820”).  Under ASC 820, fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (i.e., the “exit price”) in an orderly transaction between market participants at the measurement date.

 

Page 13

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

In determining fair value, the Company uses various valuation approaches.  ASC 820 establishes a fair value hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available.  Observable inputs are those that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company.  Unobservable inputs reflect the Company’s assumptions about the inputs market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. The fair value hierarchy is categorized into three levels based on the inputs as follows:

 

Level 1

 

Level 1 applies to assets or liabilities for which there are quoted prices in active markets for identical assets or liabilities.

 

Level 2

 

Level 2 applies to assets or liabilities for which there are inputs other than quoted prices that are observable for the asset or liability such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical assets or liabilities in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which significant inputs are observable or can be derived principally from, or corroborated by, observable market data.

 

Level 3

 

Level 3 applies to assets or liabilities for which there are unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of the assets or liabilities.

 

The carrying amount of assets and liabilities including cash and cash equivalents, short-term investments, accounts receivable, prepaids, accounts payable, accrued expenses and other current liabilities approximated their fair value as of September 30, 2026 and December 31, 2025, due to the relative short maturity of these instruments. Property and equipment, intangible assets, capital lease obligations, and goodwill are not required to be re-measured to fair value on a recurring basis. These assets are evaluated for impairment if certain triggering events occur. If such evaluation indicates that impairment exists, the respective asset is written down to its fair value.

 

The following table presents information about the Company’s assets measured at fair value on a recurring basis as of September 30, 2026 and December 31, 2025:

 

    Quoted Prices in Active     Significant              
    Markets     Other     Significant     Balance  
    for Identical     Observable     Unobservable     as of  
    Assets     Inputs     Inputs     September 30,  
    (Level 1)     (Level 2)     (Level 3)     2026  
Assets                                
Cash equivalents and restricted cash invested in money market funds and treasury bills   $ 52,049     $         -     $       -     $ 52,049  

 

    Quoted Prices in Active     Significant              
    Markets     Other     Significant     Balance  
    for Identical     Observable     Unobservable     as of  
    Assets     Inputs     Inputs     December 31,  
    (Level 1)     (Level 2)     (Level 3)     2025  
Assets                                
Cash equivalents invested in money market funds and treasury bills   $ 32,953     $       -     $           -     $      32,953  

 

Page 14

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

NOTE H – ACCOUNTS AND OTHER RECEIVABLES, NET

 

The following table presents information regarding the Company’s accounts and other receivables as of September 30, 2026 and December 31, 2025:

 

    (in thousands)  
    September 30,
2026
    December 31,
2025
 
Trade receivables   $ 13,803     $ 24,508  
Unbilled receivables     3,905       -  
Allowance for credit losses and commission adjustments     (12,106 )     (11,215 )
Accounts and other receivables, net   $ 5,602     $ 13,293  

 

Contract receivables under “Revenue from Contracts with Customers (“ASC Topic 606”)” consist of trade receivables and unbilled receivables. Trade receivables include amounts due for shipped products and services rendered. Unbilled receivables represent variable consideration recognized in accordance with ASC Topic 606 but not yet billable. Amounts recorded – billed and unbilled - under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.

  

Allowance for credit losses and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement.

 

NOTE I – INVENTORIES, NET

 

Inventories, net of reserves, consist of the following:

 

    (in thousands)  
    September 30, 2026     December 31, 2025  
Raw materials   $ 437     $ 492  
Work in process     40       57  
Finished goods     335       284  
    $ 812     $ 833  

 

The Company maintained reserves for slow moving inventories of $214,000 and $169,000 at September 30, 2026 and December 31, 2025, respectively.

 

NOTE J – GOODWILL AND OTHER INTANGIBLES

 

Goodwill is attributable to the FGE reporting unit within the Equipment segment. The components of the change in goodwill are as follows:

 

    (in thousands)  
    Nine Months Ended     Year Ended  
    September 30, 2026     December 31, 2025  
Beginning of period   $ 1,225     $ 1,176  
Foreign currency translation adjustment     54       49  
End of period   $ 1,279     $ 1,225  

 

Page 15

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following table:

 

  (in thousands)  
    September 30, 2026     December 31, 2025  
Customer-related            
Costs   $ 800     $ 800  
Accumulated amortization     (800 )     (800 )
      -       -  
                 
Patents and Technology                
Costs     1,894       1,894  
Accumulated amortization     (1,894 )     (1,894 )
      -       -  
                 
Software                
Costs     4,062       3,108  
Accumulated amortization     (2,172 )     (1,853 )
      1,890       1,255  
                 
Total   $ 1,890     $ 1,255  

 

Patents and technology are amortized on a straight-line basis over their estimated useful lives of ten and eight years, respectively. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other customer-related intangible assets is amortized on a straight-line basis over the asset’s estimated economic life of seven years. Software costs are amortized on a straight-line basis over its expected useful life of five years.

 

Amortization expense amounted to $111,000 and $13,000 for the three months ended September 30, 2026 and 2025, respectively, and $319,000 and $46,000 for the nine months ended September 30, 2026 and 2025, respectively.

 

Amortization of intangibles for the next five years is:

 

Years ending December 31,   (in thousands)  
Remainder of 2026     124  
2027     496  
2028     493  
2029     447  
2030     258  
Thereafter     72  
    $          1,890  

 

Page 16

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

NOTE K – OTHER ASSETS, NET

 

Other assets, net consist of the following at September 30, 2026 and December 31, 2025:

 

    (in thousands)  
    September 30,
2026
    December 31,
2025
 
Deferred commission expense - noncurrent   $ 4,445     $ 4,433  
Trade receivables - noncurrent     914       1,530  
Other, net of allowance for loss on loan receivable of $412 at September 30, 2026 and December 31, 2025     26       26  
    $ 5,385     $ 5,989  

 

NOTE L – ACCRUED EXPENSES AND OTHER LIABILITIES

 

Accrued expenses and other liabilities consist of the following at September 30, 2026 and December 31, 2025:

 

    (in thousands)  
    September 30,
2026
    December 31,
2025
 
Accrued compensation   $ 1,497     $ 3,739  
Accrued expenses - other     1,580       2,405  
Order reduction liability     518       1,287  
Other liabilities     1,501       921  
    $ 5,096     $ 8,352  

 

NOTE M - DEFERRED REVENUE

 

The changes in the Company’s deferred revenues are as follows:

 

    (in thousands)  
    Nine Months
Ended
    Year Ended  
    September 30,
2026
    December 31,
2025
 
Deferred revenue at beginning of period   $ 38,595     $ 34,894  
Net additions:                
Deferred extended service contracts     -       (1 )
Deferred commission revenues     13,356       17,833  
Recognized as revenue:                
Deferred extended service contracts     -       -  
Deferred commission revenues     (10,411 )     (14,131 )
Deferred revenue at end of period     41,540       38,595  
Less: current portion     21,118       19,018  
Long-term deferred revenue at end of period   $ 20,422     $ 19,577  

 

Page 17

 

 

Vaso Corporation and Subsidiaries

 

Notes to Condensed Consolidated Financial Statements (unaudited)

 

NOTE N – RELATED-PARTY TRANSACTIONS

 

The Company uses the equity method to account for its interest in EECP Global as it has the ability to exercise significant influence over the entity and reports its share of EECP Global operations in Other Income (Expense) on its condensed consolidated statements of operations. For the three months ended September 30, 2026 and 2025, the Company’s share of EECP Global’s loss was approximately $88,000 and $109,000, respectively, and for the nine months ended September 30, 2026 and 2025, the Company’s share of EECP Global’s loss was approximately $186,000 and $220,000, respectively, and included in Other (Expense) Income in its condensed consolidated statements of operations. At September 30, 2026 and December 31, 2025, the Company recorded a net receivable from related parties of approximately $1,410,000 and $910,000, respectively, on its condensed consolidated balance sheets for amounts due from EECP Global for fees and cost reimbursements net of amounts due to EECP Global for receivables collected on its behalf.

 

NOTE O – COMMITMENTS AND CONTINGENCIES

 

Sales representation agreement

 

In December 2025, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010 and previously extended in 2012, 2015, 2017 and 2021. The amendment extended the term of the original agreement, which began on July 1, 2010, through December 31, 2030, subject to early termination by GEHC without cause with certain conditions. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GEHC diagnostic imaging and ultrasound products to specific market accounts in all 50 states of the United States and the District of Columbia. The circumstances under which early termination of the agreement may occur with cause include: not materially achieving certain sales goals, not maintaining a minimum number of sales representatives, and not meeting various legal and GEHC policy requirements.

 

Employment Agreements

 

On December 31, 2022, the Company executed an Employment Agreement with the President of its VasoHealthcare subsidiary, Ms. Jane Moen, which provides for a twenty-seven month initial term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond the earlier of December 31, 2026 or the termination of the GEHC Agreement. The Employment Agreement provides for annual base compensation of $350,000. Ms. Moen is eligible to receive bonuses for each fiscal year during the employment term. The amount and the occasion for payment of such bonuses, if any, is based on employment status as well as achieving certain operating targets. Ms. Moen is also eligible for an award under any long-term incentive compensation plan and grants of options and awards of shares of the Company’s stock, as determined at the Board of Directors’ discretion. The Employment Agreement further provides for reimbursement of certain expenses, and certain severance benefits in the event of termination prior to the expiration date of the Employment Agreement.

 

Page 18

 

 

Vaso Corporation and Subsidiaries

 

ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

The information contained in this report contains forward-looking statements (as such term is defined in the Securities Exchange Act of 1934 and the regulations thereunder). These forward-looking statements may include projections of, or guidance on, the Company’s future financial performance, expected levels of future revenue and expenses, anticipated growth strategies, and anticipated trends in the Company’s business or financial results. When used in this report, words such as “anticipates”, “continue”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential”, “future”, “intends”, the negative of these terms and similar expressions identify forward-looking statements. Any forward-looking statement made by the Company in this document is based only on the Company’s current expectations, estimates and projections about future events and financial trends affecting the financial condition of its business based on information currently available to the Company and speaks only as of the date when made. Forward-looking statements are not historical facts or guarantees of future performance. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict, many of which are outside of the Company’s control. Actual results may differ materially from this forward-looking information and therefore, should not be unduly relied upon. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the possibility of a downturn or disruptions in the U.S. economy; the impact of US tariff policies; the effect of the dramatic changes taking place in IT and healthcare; continuation of the GEHC agreement; the impact of competitive technology and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; and the risk factors reported from time to time in the Company’s SEC reports. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.

 

Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.

 

General Overview

 

Our Business Segments

 

Vaso Corporation (“Vaso”) was incorporated in Delaware in July 1987. Prior to the divestitures of VasoHealthcare IT Corp in November 2025 and NetWolves in July 2026, we principally operated in three distinct business segments in the healthcare and information technology industries. We managed and evaluated our operations, and reported our financial results, through these three business segments.

 

· IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc. (“VasoTechnology”), primarily focused on managed network technology services. As described in Note C, the NetWolves managed network services operations are reported as discontinued operations and no longer included in segment disclosures. Historical results of VasoHeathcare IT Corp, the other operation within the IT segment and which was sold in November 2025, continue to be presented in segment disclosures;

 

· Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GE HealthCare Technologies, Inc. (“GEHC”) into the healthcare provider middle market; and

 

· Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., which in turn operates through Vasomedical Solutions, Inc. for domestic business and Vasomedical Global Corp. for international business, respectively, primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software.

 

Page 19

 

 

Vaso Corporation and Subsidiaries

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.

 

Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see Note B to the consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 31, 2026. There have been no material changes to our critical accounting estimates since the filing of that report.

 

Unless otherwise noted, this Management’s Discussion and Analysis of Financial Condition and Results of Operations relates solely to our continuing operations and does not include the operations of NetWolves. See Note C – Discontinued Operations of the notes to the unaudited condensed consolidated financial statements for additional information about the disposal group. The IT segment reported no amounts in 2026 as a result of the divestiture of VasoHealthcare IT in November 2025. Certain corporate overhead costs previously allocated to NetWolves were removed from the results of the discontinued operations as such costs will continue, and were reallocated to the professional sales services and equipment segments.

 

Results of Operations – For the Three Months Ended September 30, 2026 and 2025

 

Revenues

 

Total revenue for the three months ended September 30, 2026 and 2025 was $10,786,000 and $12,377,000, respectively, representing a decrease of $1,591,000, or 13%, year-over-year. On a segment basis, revenue in the IT and professional sales services segments decreased by $938,000 and $672,000, respectively, and revenue in the equipment segment increased by $19,000.

 

Commission revenues in the professional sales service segment were $10,148,000 in the third quarter of 2026, a decrease of $672,000, or 6%, as compared to $10,820,000 in the same quarter of 2025. The decrease in commission revenues was due primarily to a decrease in the volume of underlying equipment delivered by GEHC during the period, as well as a lower blended commission rate applicable to such deliveries. The Company only recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GEHC prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheets. As of September 30, 2026, $41,540,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheets, of which $20,422,000 was long-term. As of September 30, 2025, $39,412,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheets, of which $21,854,000 was long-term. The increase in deferred revenue was principally due to new orders exceeding deliveries during the period.

 

Page 20

 

 

Vaso Corporation and Subsidiaries

 

Revenue in the equipment segment increased by $19,000, or 3%, to $638,000 for the three-month period ended September 30, 2026 from $619,000 for the same period of the prior year, due primarily to higher ARCS® subscription revenues in our US operations, partially offset by lower deliveries in our China operations.

 

Gross Profit

 

Gross profit for the three months ended September 30, 2026 and 2025 was $8,564,000, or 79% of revenue, and $9,550,000, or 77% of revenue, respectively, representing a decrease of $986,000, or 10%, year-over-year. On a segment basis, gross profit in the IT, professional sales service, and equipment segments decreased by $387,000, or 100%; $554,000, or 6%; and $45,000, or 11%, respectively.

 

Professional sales service segment gross profit was $8,193,000, or 81% of segment revenue, for the three months ended September 30, 2026 as compared to $8,747,000, or 81% of the segment revenue, for the three months ended September 30, 2025, reflecting a decrease of $554,000, or 6%. The decrease was due to lower commission revenue, as well as a lower blended commission rate, offset by lower commission expenses. Cost of commissions in the professional sales service segment of $1,955,000 and $2,073,000, for the three months ended September 30, 2026 and 2025, respectively, reflected commission expense associated with recognized commission revenues.

 

Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the condensed consolidated balance sheets until the related commission revenue is recognized.

 

Equipment segment gross profit decreased to $371,000, or 58% of segment revenues, for the third quarter of 2026 compared to $416,000, or 67% of segment revenues, for the same quarter of 2025. The $45,000, or 11%, decrease in gross profit was primarily the result of higher ARCS® subscription costs in the US market and lower gross margin in our China operations due mainly to higher inventory obsolescence costs.

 

Operating Income (Loss)

 

Operating income (loss) for the three months ended September 30, 2026 was $632,000 compared to $1,380,000 for the same quarter in 2025, representing a decrease of $748,000, or 54%, due primarily to decreased gross profit in the professional sales service and equipment segments and higher research and development (“R&D”) costs, partially offset by lower selling, general and administrative (“SG&A”) costs due to the cessation of VHC-IT operations in November 2025.

 

Operating income in the professional sales service segment decreased to $1,331,000 in the three-month period ended September 30, 2026 as compared to operating income of $2,016,000 in the same period of 2025, due to lower gross profit and higher SG&A costs. The equipment segment reported an operating loss of $300,000 in the third quarter of 2026, compared to an operating loss of $179,000 in the third quarter 2025, a decrease of $121,000, primarily due to higher R&D spending and lower gross profit.

 

SG&A costs for the three months ended September 30, 2026 and 2025 were $7,696,000 and $8,024,000, respectively, representing a decrease of $328,000, or 4% year-over-year. On a segment basis, there were no SG&A costs in the IT segment in the third quarter of 2026 and $555,000 in the third quarter of 2025; SG&A costs in the professional sales service segment increased by $131,000 due mainly to travel costs; and SG&A costs in the equipment segment decreased by $14,000 due primarily to lower personnel costs. Corporate SG&A costs not allocated to segments increased $110,000 due mainly to higher director fees and insurance costs.

 

Research and development expenses were $236,000, or 2% of revenues, for the third quarter of 2026, an increase of $90,000, or 62%, from $146,000, or 1% of revenues, for the third quarter of 2025. The increase was primarily attributable to higher product development expenses in the equipment segment.

 

Page 21

 

 

Vaso Corporation and Subsidiaries

 

Adjusted EBITDA

 

We utilize Adjusted EBITDA in evaluating our performance internally, and this non-GAAP financial measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in the Company’s industry. Management believes that this non-GAAP financial measure, in addition to GAAP measures, is also useful to investors to evaluate the Company’s results.

 

Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for net income (loss), which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Investors should recognize that the Company’s presentation of this non-GAAP financial measure might not be comparable to similarly-titled measures of other companies limiting its usefulness as a comparative measure.

 

A reconciliation of net income from continuing operations to Adjusted EBITDA is set forth below:

 

    (in thousands)  
    Three Months Ended
September 30,
 
    2026     2025  
    (unaudited)     (unaudited)  
Net income from continuing operations   $ 568     $ 1,553  
Interest expense (income), net     (391 )     (308 )
Income tax expense     363       25  
Depreciation and amortization     123       54  
Share-based compensation     28       8  
Adjusted EBITDA from continuing operations   $ 691     $ 1,332  

 

Adjusted EBITDA from continuing operations decreased by $641,000, to $691,000 in the quarter ended September 30, 2026 from $1,332,000 in the quarter ended September 30, 2025. The decrease was primarily attributable to the decrease in net income partially offset by higher income tax expense.

 

A reconciliation of net income from discontinued operations to Adjusted EBITDA is set forth below:

 

    Three Months Ended
September 30,
 
    2026     2025  
    (unaudited)     (unaudited)  
Net income from discontinued operations   $ 1,104     $ 158  
Interest expense (income), net     (1 )     (8 )
Income tax expense     1,237       10  
Depreciation and amortization     42       125  
Adjusted EBITDA from discontinued operations   $ 2,382     $ 285  

 

Adjusted EBITDA from discontinued operations increased by $2.097,000, to $2,382,000 in the quarter ended September 30, 2026 from $285,000 in the quarter ended September 30, 2025. The increase was attributable mainly to the higher net income arising from the gain on sale of NetWolves and higher income tax expense.

 

Page 22

 

 

Vaso Corporation and Subsidiaries

 

Interest and Other Income (Expense)

 

Interest and other income (expense) for the three months ended September 30, 2026 was $299,000 as compared to $198,000 for the corresponding period of 2025. The increase in interest and other income (expense) was due primarily to higher interest income resulting from higher money market and US Treasury bill balances.

 

Income Tax Expense

 

For the three months ended September 30, 2026, we recorded income tax expense of $363,000 as compared to $25,000 for the corresponding period of 2025. The $338,000 increase was due mainly to higher deferred tax expense.

 

Net Income from Continuing Operations

 

Net income from continuing operations for the three months ended September 30, 2026 was $568,000 as compared to $1,553,000 for the three months ended September 30, 2025, representing a decrease of $985,000. Income per share of $0.00 and $0.01 was recorded in the three-month periods ended September 30, 2026 and 2025, respectively. The principal cause of the decrease in net income from continuing operations was the decrease in gross profit and increase in income tax expense, partially offset by the decrease in SG&A costs.

 

Results of Operations – For the Nine Months Ended September 30, 2026 and 2025

 

Revenues

 

Total revenue for the nine months ended September 30, 2026 and 2025 was $31,767,000 and $32,841,000, respectively, representing a decrease of $1,074,000, or 3%, year-over-year. On a segment basis, revenue in the IT segment decreased by $2,983,000 due to the sale of VHC-IT operations in November 2025; revenues in the professional sales service and equipment segments increased by $1,608,000 and $301,000, respectively.

 

Commission revenues in the professional sales service segment were $29,877,000 in the first nine months of 2026, an increase of $1,608,000, or 6%, as compared to $28,269,000 in the first nine months of 2025. The increase in commission revenues was due to an increase in the volume of underlying equipment delivered by GEHC during the period, partially offset by a lower blended commission rate applicable to such deliveries. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GEHC prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of September 30, 2026, $41,540,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $20,422,000 was long-term. As of September 30, 2025, $39,412,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $21,854,000 was long-term. The increase in deferred revenue is principally due to new orders exceeding deliveries during the period.

 

Revenue in the equipment segment increased by $301,000, or 19%, to $1,890,000 for the nine-month period ended September 30, 2026 from $1,589,000 for the same period of the prior year, due to both higher ARCS® subscription revenues in our US operations and higher deliveries in our China operations.

 

Page 23

 

 

Vaso Corporation and Subsidiaries

 

Gross Profit

 

Gross profit for the nine months ended September 30, 2026 and 2025 was $24,974,000, or 79% of revenue, and $25,128,000, or 77% of revenue, respectively, representing a decrease of $154,000, or less than 1% year-over-year. On a segment basis, gross profit in the IT segment decreased $1,272,000 as there were no IT operations included in 2026 numbers; gross profit in the professional sales service segment increased $1,158,000, or 5%; and gross profit in the equipment segment decreased $40,000, or 4%.

 

Professional sales service segment gross profit was $23,885,000, or 80% of segment revenue, for the nine months ended September 30, 2026 as compared to $22,727,000, or 80% of the segment revenue, for the nine months ended September 30, 2025, reflecting an increase of $1,158,000, or 5%. The increase was due to higher commission revenue, partially offset by a lower blended commission rate. Cost of commissions in the professional sales service segment of $5,992,000 and $5,542,000, for the nine months ended September 30, 2026 and 2025, respectively, reflected commission expense associated with recognized commission revenues.

 

Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the condensed consolidated balance sheets until the related commission revenue is recognized.

 

Equipment segment gross profit decreased to $1,089,000, or 58% of segment revenues, for the first nine months of 2026 compared to $1,129,000, or 71% of segment revenues, for the same period in 2025. The $40,000, or 4%, decrease in gross profit was primarily the result of higher ARCS® subscription costs in the US market.

 

Operating Income (Loss)

 

Operating income for the nine months ended September 30, 2026 and 2025 was $552,000 and $862,000, respectively, representing a decrease of $310,000 as a combined result of lower gross profit and higher operating costs (below), year-over-year.

 

Operating income in the professional sales service segment decreased $140,000 to $2,677,000 in the nine-month period ended September 30, 2026 as compared to operating income of $2,817,000 in the same period of 2025, due to higher SG&A costs partially offset by higher gross profit. The equipment segment reported an operating loss of $895,000 in the first nine months of 2026, compared to an operating loss of $621,000 in the first nine months of 2025, an increase in loss of $274,000, due mainly to higher SG&A and R&D costs. The IT segment recorded an operating loss of $0 and $220,000 in the first nine months of 2026 and 2025, respectively.

 

SG&A costs for the nine months ended September 30, 2026 and 2025 were $23,791,000 and $23,775,000, respectively, representing an increase of $16,000, or less than 1% year-over-year. On a segment basis, SG&A costs in the IT segment were $0 and $1,492,000 in the first nine months of 2026 and 2025, respectively; SG&A costs in the professional sales service segment increased by $1,297,000 due mainly to higher personnel and travel costs in the diagnostic imaging sector; and SG&A costs in the equipment segment increased by $94,000 due primarily to higher personnel costs in our China operations. Corporate costs not allocated to segments increased $117,000 due mainly to higher director, insurance and legal costs.

 

R&D expenses were $631,000, or 2% of revenues, for the first nine months of 2026, an increase of $140,000, or 28%, from $491,000, or 1% of revenues, for the first nine months of 2025. The increase is primarily attributable to higher product development expenses in the equipment segment.

 

Adjusted EBITDA

 

We utilize Adjusted EBITDA in evaluating our performance internally, and this non-GAAP financial measure is frequently used by securities analysts, investors and other interested parties in the evaluation of companies in the Company’s industry. Management believes that this non-GAAP financial measure, in addition to GAAP measures, is also useful to investors to evaluate the Company’s results.

 

Page 24

 

 

Vaso Corporation and Subsidiaries

 

Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for net income (loss), which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Investors should recognize that the Company’s presentation of this non-GAAP financial measure might not be comparable to similarly-titled measures of other companies limiting its usefulness as a comparative measure.

 

A reconciliation of net income from continuing operations to Adjusted EBITDA is set forth below:

 

    Nine Months Ended
September 30,
 
    2026     2025  
    (unaudited)     (unaudited)  
Net income from continuing operations   $ 683     $ 1,411  
Interest expense (income), net     (930 )     (836 )
Income tax expense     625       80  
Depreciation and amortization     357       180  
Share-based compensation     47       24  
Adjusted EBITDA from continuing operations   $ 782     $ 859  

 

Adjusted EBITDA from continuing operations decreased by $78,000 to $782,000 in the nine months ended September 30, 2026 from $860,000 in the nine months ended September 30, 2025. The decrease was primarily attributable to lower net income, partially offset by higher income tax expense and higher depreciation and amortization.

 

A reconciliation of net income (loss) from discontinued operations to Adjusted EBITDA is set forth below:

 

    Nine Months Ended
September 30,
 
    2026     2025  
    (unaudited)     (unaudited)  
Net income (loss) from discontinued operations   $ 646     $ (972 )
Interest expense (income), net     (10 )     (26 )
Income tax expense     1,108       35  
Depreciation and amortization     279       351  
Share-based compensation     -       1  
Adjusted EBITDA from discontinued operations   $ 2,023     $ (611 )

 

Adjusted EBITDA from discontinued operations increased by $2,634,000 to $2,023,000 in the nine-month period ended September 30, 2026 from ($611,000) in the same period ended September 30, 2025. The increase was primarily attributable to the change from net loss to net income in the nine months ended September 30, 2026, due primarily to the $3,494,000 gain on sale of NetWolves and higher income tax expense.

 

Interest and Other Income (Expense)

 

Interest and other income (expense) for the nine months ended September 30, 2026 was $756,000 as compared to $629,000 for the corresponding period of 2025. The increase in interest and other income (expense) was due primarily to higher interest income resulting from higher money market and US Treasury bill balances, partially offset by lower loss at EECP Global.

 

Income Tax Expense

 

For the nine months ended September 30, 2026, we recorded income tax expense of $625,000 as compared to income tax expense of $80,000 for the corresponding period of 2025. The increase was due mainly to higher deferred tax expense.

 

Page 25

 

 

Vaso Corporation and Subsidiaries

 

Net Income from Continuing Operations

 

Net income from continuing operations for the nine months ended September 30, 2026 was $683,000 as compared to $1,411,000 for the nine months ended September 30, 2025, representing a decrease of $728,000, or 52%. Income per share of $0.00 and $0.01 was recorded in the nine-month periods ended September 30, 2026 and 2025, respectively. The principal cause of the decrease was higher income tax expense and higher R&D costs, partially offset by higher interest income.

 

Liquidity and Capital Resources

 

Cash and Cash Flow

 

We have financed our operations from working capital. At September 30, 2026, we had cash and cash equivalents of $49,947,000 and working capital of $36,386,000, compared to cash and cash equivalents of $34,081,000 and working capital of $21,714,000 at December 31, 2025.

 

Cash provided by operating activities was $6,541,000, which consisted of net income after adjustments to reconcile net income to net cash of $443,000 and cash provided by operating assets and liabilities of $6,098,000, during the nine months ended September 30, 2026, compared to cash provided by operating activities of $9,012,000 for the same period in 2025. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $7,717,000 and an increase in deferred revenue of $2,946,000; partially offset by decreases in accrued commissions and accrued expenses of $1,228,000 and $3,364,000, respectively.

 

Cash provided by investing activities during the nine-month period ended September 30, 2026 was $11,545,000, resulting from $12,806,000 in proceeds from sale of NetWolves, offset by $1,261,000 for the purchase of equipment and software.

 

Cash used in financing activities during the nine-month period ended September 30, 2026 was $293,000 for the repayment of notes payable and $22,000 for the payment of payroll taxes financed by the withholding of employee stock shares.

 

Liquidity

 

Our principal sources of liquidity are our cash and cash equivalents and cash generated from operations, which is substantially dependent on the GEHC Agreement. Our material cash requirements consist primarily of personnel and other operating costs and capital expenditures. We believe these sources will be sufficient to satisfy our material cash requirements for at least the next twelve months and thereafter.

 

ITEM 3 - Quantitative and Qualitative Disclosures About Market Risk.

 

Not applicable to smaller reporting companies.

 

ITEM 4 - CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2026 and have concluded that the Company’s disclosure controls and procedures were effective as of September 30, 2026. 

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in the Company’s internal control over financial reporting during the Company’s fiscal quarter ended September 30, 2026 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

Page 26

 

 

Vaso Corporation and Subsidiaries

 

PART II - OTHER INFORMATION

 

ITEM 1 – LEGAL PROCEEDINGS

 

From time to time, the Company may become involved in legal proceedings arising in the ordinary course of business. The Company is not currently a party to any legal proceedings that management believes, individually or in the aggregate, would have a material adverse effect on the Company’s business, financial condition or results of operations.

 

ITEM 1A. Risk Factors.

 

Not applicable to smaller reporting companies.

 

ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds.

 

Date   Shares Purchased     Average Share Price  
October, 2026     79,810     $ 0.27  

 

Shares were withheld to satisfy tax withholding obligations upon vesting of restricted stock.

 

ITEM 3. Defaults Upon Senior Securities.

 

None.

 

ITEM 4. Mine Safety Disclosures.

 

Not applicable.

 

ITEM 5. Other Information.

 

During the three months ended September 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement”, as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 6 – EXHIBITS

 

Exhibits      
3(i) (a)   Restated Certificate of Incorporation (incorporated by reference to Registration Statement on Form S-1, No. 33-46377 (effective 7/12/94)).
  (b)   Certificate of Designations of Preferences and Rights of Series E Convertible Preferred Stock (incorporated by reference to Report on Form 8-K dated June 21, 2010).
  (c)   Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Report on Form 10-Q for the quarter ended September 30, 2016).
3(ii)     Bylaws (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).
4     Specimen Certificate for Common Stock (Incorporated by reference to Registration Statement on Form S-18, No. 33-24095).
31.1     Certification of the Chief Executive Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2     Certification of the Chief Financial Officer pursuant to Rule 13a-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1       Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2     Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS     XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCH     XBRL Taxonomy Extension Schema Document
101.CAL     XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF     XBRL Taxonomy Extension Definition Linkbase Document
101.LAB     XBRL Taxonomy Extension Label Linkbase Document
101.PRE     XBRL Taxonomy Extension Presentation Linkbase Document
104     Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

 

Page 27

 

 

Vaso Corporation and Subsidiaries

 

In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VASO CORPORATION
     
  By: /s/ Jun Ma
    Jun Ma
    President and Chief Executive Officer
    (Principal Executive Officer)
     
    /s/ Jonathan Newton
    Jonathan Newton
    Chief Financial Officer and Principal Accounting Officer

 

Date: November 16, 2026

 

Page 28